| Browse All

HCW Biologics Inc. (HCWB)

Healthcare | Biotechnology | Miramar, United States | NasdaqCM
0.38 USD -0.03 (-7.299%) ⇩ (April 21, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:☆☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | April 19, 2026, 1:11 a.m. EDT

Despite a recent short-term price spike and positive clinical data, the bearish macro-upside is severe: the stock is trading near its 52-week low (-80% from highs), technicals show a major gap below the 50-day average, and the quantitative forecast model predicts a -31% price drop over the next 45 days with high statistical significance (Ljung-Box p-value ~0). Furthermore, the balance sheet is critically distressed with negative operating cash flow, insufficient liquidity (current ratio 0.1), and an unsustainable payment structure, making this a risky 'findings-driven' rebound rather than a fundamental investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.234526
AutoARIMA0.252409
MSTL0.737623
AutoETS0.742681

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 44%
H-stat 9.91
Ljung-Box p 0.000
Jarque-Bera p 0.368
Excess Kurtosis -0.24
Attribute Value
Sector Healthcare
Debt to Equity Ratio 246.285
Revenue per Share 0.026
Market Cap 2,565,693
Forward P/E -0.69
Beta 0.91
Website https://www.hcwbiologics.com

Info Dump

Attribute Value
52 Week Change -0.9519546
Address1 2,929 North Commerce Parkway
All Time High 311.0
All Time Low 0.25
Ask 0.4966
Ask Size 2
Average Daily Volume10 Day 566,020
Average Daily Volume3 Month 8,403,354
Average Volume 8,403,354
Average Volume10Days 566,020
Beta 0.905
Bid 0.2877
Bid Size 2
Book Value 0.843
City Miramar
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.381
Current Ratio 0.108
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 0.4196
Day Low 0.3741
Debt To Equity 246.285
Display Name HCW Biologics
Ebitda -12,620,739
Ebitda Margins 0.0
Enterprise To Ebitda -0.588
Enterprise To Revenue 136.865
Enterprise Value 7,422,444
Eps Forward -0.55
Eps Trailing Twelve Months -9.54
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 954 842 2037
Fifty Day Average 0.5502
Fifty Day Average Change -0.16919997
Fifty Day Average Change Percent -0.3075245
Fifty Two Week Change Percent -95.19546
Fifty Two Week High 17.8
Fifty Two Week High Change -17.418999
Fifty Two Week High Change Percent -0.9785955
Fifty Two Week Low 0.25
Fifty Two Week Low Change 0.13100001
Fifty Two Week Low Change Percent 0.52400005
Fifty Two Week Range 0.25 - 17.8
Financial Currency USD
First Trade Date Milliseconds 1,626,787,800,000
Float Shares 6,100,492
Forward Eps -0.55
Forward P E -0.69272727
Free Cashflow -15,625,519
Full Exchange Name NasdaqCM
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.19999
Gross Profits 10,846
Has Pre Post Market Data 1
Held Percent Insiders 0.08604
Held Percent Institutions 0.06782
Implied Shares Outstanding 6,734,104
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-07-20
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,744,329,600
Last Split Factor 1:40
Long Business Summary HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Long Name HCW Biologics Inc.
Market us_market
Market Cap 2,565,693
Market State PRE
Max Age 86,400
Message Board Id finmb_628452149
Most Recent Quarter 1,767,139,200
Net Income To Common -22,298,702
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 2,519,228
Number Of Analyst Opinions 1
Open 0.4
Operating Cashflow -13,391,617
Operating Margins -183.70314
Payout Ratio 0.0
Phone 954 842 2024
Pre Market Change 0.027999997
Pre Market Change Percent 7.3490806
Pre Market Price 0.409
Pre Market Time 1,776,849,580
Previous Close 0.411
Price Hint 4
Price To Book 0.45195732
Price To Sales Trailing12 Months 47.309578
Profit Margins 0.0
Quick Ratio 0.094
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.03
Regular Market Change Percent -7.29927
Regular Market Day High 0.4196
Regular Market Day Low 0.3741
Regular Market Day Range 0.3741 - 0.4196
Regular Market Open 0.4
Regular Market Previous Close 0.411
Regular Market Price 0.381
Regular Market Time 1,776,801,601
Regular Market Volume 303,593
Return On Assets -0.31189
Revenue Growth -0.932
Revenue Per Share 0.026
Sand P52 Week Change 0.3140242
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 6,734,104
Shares Percent Shares Out 0.0164
Shares Short 110,641
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 57,608
Short Name HCW Biologics Inc.
Short Percent Of Float 0.0176
Short Ratio 0.0
Source Interval 15
State FL
Symbol HCWB
Target High Price 2.0
Target Low Price 2.0
Target Mean Price 2.0
Target Median Price 2.0
Total Cash 1,952,464
Total Cash Per Share 0.29
Total Debt 6,809,215
Total Revenue 54,232
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -9.54
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.527035
Two Hundred Day Average Change -2.146035
Two Hundred Day Average Change Percent -0.8492304
Type Disp Equity
Volume 303,593
Website https://www.hcwbiologics.com
Zip 33,025